A Case of Multicentric Castleman's Disease Having Lung Lesion Successfully Treated with Humanized Anti-interleukin-6 Receptor Antibody, Tocilizumab

被引:20
作者
Higuchi, Tomoaki [1 ]
Nakanishi, Takashi [1 ]
Takada, Kunio [1 ]
Matsumoto, Mitsuyo [1 ]
Okada, Makoto [1 ]
Horikoshi, Hideyuki [1 ]
Suzuki, Kimihiro [1 ]
机构
[1] Natl Def Med Coll, Dept Internal Med, Div Rheumatol, Tokorozawa, Saitama 3598513, Japan
关键词
Giant Lymph Node Hyperplasia; Biological Products; Immunosuppressive Agents; LYMPH-NODE HYPERPLASIA; CYCLOSPORINE; EXPRESSION;
D O I
10.3346/jkms.2010.25.9.1364
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This report presents the case of a patient demonstrating multicentric Castleman's disease (MCD) with a lung lesion that was successfully treated with an anti-interleukin-6 receptor antibody, tocilizumab in combination with corticosteroid and tacrolimus. A 43-yr-old female with abnormal shadows on a chest X-ray was referred to the hospital for further examination. She was diagnosed as having MCD based on the characteristic pathology of inguinal lymph node, lung lesions, laboratory data, and undifferentiated arthritis. Corticosteroid and rituximab therapy did not fully ameliorate the symptoms; thus, the therapeutic regimen was changed to include tocilizumab, oral corticosteroid and tacrolimus. This regimen resulted in clinical remission and the dose of tocilizumab and corticosteroid could be tapered. Tocilizumab in combination with corticosteroid and tacrolimus may therefore be a beneficial treatment regimen for lung lesions associated with MCD.
引用
收藏
页码:1364 / 1367
页数:4
相关论文
共 21 条
  • [1] Akahane Daigo, 2006, Rinsho Ketsueki, V47, P748
  • [2] Brief communication: Rituximab in HIV-associated multicentric Castleman disease
    Bower, Mark
    Powles, Tom
    Williams, Sarah
    Davis, Tom Newsom
    Atkins, Mark
    Montoto, Silvia
    Orkin, Chloe
    Webb, Andy
    Fisher, Martin
    Nelson, Mark
    Gazzard, Brian
    Stebbing, Justin
    Kelleher, Peter
    [J]. ANNALS OF INTERNAL MEDICINE, 2007, 147 (12) : 836 - 839
  • [3] CASTLEMAN B, 1956, CANCER-AM CANCER SOC, V9, P822, DOI 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO
  • [4] 2-4
  • [5] COCKFIELD SM, 1993, J IMMUNOL, V150, P342
  • [6] A SYSTEMIC LYMPHOPROLIFERATIVE DISORDER WITH MORPHOLOGIC FEATURES OF CASTLEMANS DISEASE - CLINICAL FINDINGS AND CLINICOPATHOLOGIC CORRELATIONS IN 15 PATIENTS
    FRIZZERA, G
    PETERSON, BA
    BAYRD, ED
    GOLDMAN, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (09) : 1202 - 1216
  • [7] Cyclosporin A decreases human macrophage interleukin-6 synthesis at post-transcriptional level
    García, JEL
    López, AMR
    de Cabo, MRM
    Rodríguez, FM
    Losada, JP
    Sarmiento, RG
    López, AJ
    Arellano, JLP
    [J]. MEDIATORS OF INFLAMMATION, 1999, 8 (4-5) : 253 - 259
  • [8] Intrathoracic multicentric Castleman disease:: CT findings in 12 patients
    Johkoh, T
    Müller, NL
    Ichikado, K
    Nishimoto, N
    Yoshizaki, K
    Honda, O
    Tomiyama, N
    Naitoh, H
    Nakamura, H
    Yamamoto, S
    [J]. RADIOLOGY, 1998, 209 (02) : 477 - 481
  • [9] KELLER AR, 1972, CANCER-AM CANCER SOC, V29, P670, DOI 10.1002/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO
  • [10] 2-#